S-1/A: Cyclacel Pharmaceuticals Eyes $10 Million Capital Raise Through Public Offering

Cyclacel Pharmaceuticals is seeking to raise up to $10 million through a public offering of common stock, warrants, and pre-funded warrants to bolster working capital.

Summary

• Cyclacel Pharmaceuticals has filed an amendment to its Form S-1 registration statement for a proposed public offering.
• The offering includes up to 5,952,380 shares of common stock and accompanying warrants to purchase up to 11,904,760 shares, or pre-funded warrants as an alternative for certain investors.
• The assumed combined public offering price is $1.68 per share and accompanying warrants.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• The offering is a best efforts offering with Roth Capital Partners, LLC acting as the exclusive placement agent.
• The offering will terminate on the earlier of the date the securities purchase agreements are entered into or May 31, 2024.
• As of December 31, 2023, the company's cash and cash equivalents were $3.4 million, which is expected to fund operations into April 2024.
• As of April 12, 2024, the company's cash balance was approximately $2.7 million.
• The company received a Nasdaq notice on March 27, 2024, regarding non-compliance with the minimum stockholders' equity requirement for continued listing.
• The company must submit a plan to regain compliance by May 10, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively seeking funding and has ongoing clinical trials, the financial situation and Nasdaq compliance issues raise concerns.

Positives

• The offering could provide Cyclacel with necessary working capital to continue operations.
• The company has retained rights to commercialize its clinical development candidates and plans to enter into selective partnership arrangements.
• The company is working to develop innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology.

Negatives

• The company's stockholders' equity is significantly below Nasdaq's minimum requirement, posing a delisting risk.
• The company's cash and cash equivalents are limited, with existing funds expected to last only into April 2024.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value of the shares they purchase in this offering and may experience additional dilution in the future.
• There is no public market for the Common Stock Warrants or pre-funded warrants being offered by us in this offering.
• The Common Stock Warrants are not exercisable until Stockholder Approval and may not have any value.
• This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.

Risks

• Failure to regain compliance with Nasdaq listing rules could lead to delisting, limiting stock liquidity and hindering future capital raising.
• The company may not be able to raise sufficient capital in this offering to meet its operational needs.
• The value of the warrants is uncertain, and they may not have any value if the stock price does not exceed the exercise price.
• The company's management has broad discretion in using the proceeds, which may not be effective.
• Investors will experience immediate and substantial dilution.
• There is no guarantee that the Stockholder Approval will ever be obtained.

Future Outlook

Assuming net proceeds of approximately $8.9 million from this offering (assuming an offering with gross proceeds of $10 million), we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs through the the first quarter of 2025 under our current business plan.

Industry Context

Cyclacel operates in the competitive biopharmaceutical industry, focusing on oncology and hematology. The company faces challenges common to the sector, including the need for substantial capital to fund research and development, clinical trials, and regulatory approvals.

Comparison to Industry Standards

• Cyclacel Pharmaceuticals, with a market capitalization significantly lower than many established pharmaceutical companies, faces greater challenges in securing funding and navigating regulatory hurdles.
• Companies like Celgene (acquired by Bristol Myers Squibb) and Gilead Sciences, with larger market caps and revenue streams, have more resources for drug development and commercialization.
• Smaller biotechs often rely on partnerships or acquisitions by larger firms to bring their products to market, a strategy Cyclacel aims to pursue selectively.

Related Party Transactions

• On December 21, 2023, in an insider private placement, we entered into an Insider Securities Purchase Agreement pursuant to which we agreed to sell in a private placement (i) 6,070 shares of common stock and warrants to purchase 6,070 shares of common stock, on the same terms as the unregistered warrants issued to certain institutional investors (the Purchasers and such warrants, the Private Warrants), to Spiro Rombotis, our Chief Executive Officer, and (ii) 1,886 shares of common stock and warrants to purchase 1,886 shares of common stock on the same terms as the Private Warrants issued to the Purchasers in the Offerings to Paul McBarron, our Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer.

Stakeholder Impact

• Shareholders face potential dilution from the offering and the risk of delisting from Nasdaq.
• Employees' job security could be affected by the company's financial stability.
• Customers may be concerned about the company's ability to continue drug development and commercialization.
• Suppliers and creditors face increased risk if the company's financial situation does not improve.

Next Steps

• The company must submit a plan to Nasdaq by May 10, 2024, to regain compliance with listing rules.
• The company will seek Stockholder Approval for the issuance of shares issuable upon exercise of the Common Stock Warrants.
• The company will proceed with the public offering, subject to market conditions and investor interest.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, capital raise, Cyclacel Pharmaceuticals, Roth Capital Partners, Nasdaq, delisting, biopharmaceutical, oncology